Search

Displaying results 3251 - 3260 of 9132 in total
  1. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays … an important role in tumor cell growth and survival.

  2. Drug

    Arzoxifene

    go.drugbank.com/drugs/DB06249
    ApprovedWithdrawn

  3. Drug

    Sodium tetradecyl sulfate

    go.drugbank.com/drugs/DB00464
    Approved

    An anionic surface-active agent used for its wetting properties in industry and used in medicine as an irritant and sclerosing agent for hemorrhoids and varicose veins.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. … A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository.

    Products: CEFIZOX IM LIDOKAINLI 500 MG FLAKON, 1 ADET, CEFIZOX IM LIDOKAINLI 1000 MG FLAKON, 1 ADET
  5. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

  6. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. … Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.

  7. Drug

    Custirsen

    go.drugbank.com/drugs/DB05487
    Investigational

    Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. … Custirsen is a benzopyran with potential antineoplastic activity.

  8. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

  9. Drug

    Cianidanol

    go.drugbank.com/drugs/DB14086
    ApprovedInvestigationalWithdrawn

    An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.

  10. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. … [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies